UKHSA RSV efficacy study.pdf May 2026

Posted on:

Dear Practice Colleagues,

Please find attached a new UKHSA study highlighting the efficacy of the maternal respiratory syncytial virus (RSV) vaccination in protecting newborn babies shows that the RSV vaccine reduces the risk of hospitalisation in newborn infants by over 80% when given at least two weeks before birth.

Maternal RSV vaccine uptake in England continues to climb, reaching 55% during the study period and the latest data showing uptake rising to 64.1% for women who gave birth in November 2025.

Materials are available to help communicate the benefits of the maternal vaccine programme, including the RSV vaccine, on the Campaign Resource Centre

Please contact our team at england.londonimms@nhs.net with any queries.

Kind regards

London Immunisation Team

NHS England – London Region

UKHSA RSV efficacy study.pdf May 2026Download

This website is for healthcare professions only.

It is not for public use.

Feedback
Feedback
How would you rate your experience?
Do you have any additional comment?
Next
Enter your email if you'd like us to contact you regarding with your feedback.
Back
Submit
Thank you for submitting your feedback!